Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
The combination regimen demonstrated promising efficacy in treating unresectable HCC, accompanied by manageable safety profiles. Furthermore, the results of this investigation suggest that AFP holds promise as predictive biomarkers for this treatment strategy.
Authors
- Peng Yu (ORCID: https://orcid.org/0000-0002-3948-3340)
- Lingzhan Meng (ORCID: https://orcid.org/0000-0003-2612-0919)
- Yanling Shao
- Yingjie Ji (ORCID: https://orcid.org/0009-0004-3564-1710)
- Zhenyu Zhu
- Li Cao (ORCID: https://orcid.org/0000-0002-3709-873X)
- Hu Li (ORCID: https://orcid.org/0000-0002-7917-7807)
- Yan Jin (ORCID: https://orcid.org/0000-0001-6282-7095)
- Yinjie Gao (ORCID: https://orcid.org/0000-0001-6034-1999)
- Bin Shi (ORCID: https://orcid.org/0000-0002-3643-9475)
- Zizheng Wang (ORCID: https://orcid.org/0000-0002-6967-0630)
Institutions
- Second Military Medical University (CN)
- Chinese PLA General Hospital (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1007/s00262-024-03857-5
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Natural Science Foundation of China